Weighted Average Number of Shares Outstanding, Diluted of PharmaCyte Biotech, Inc. from 2012 to Q2 2025

Taxonomy & unit
us-gaap: shares
Description
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
Summary
PharmaCyte Biotech, Inc. quarterly/annual Weighted Average Number of Shares Outstanding, Diluted history and change rate from 2012 to Q2 2025.
  • PharmaCyte Biotech, Inc. Weighted Average Number of Shares Outstanding, Diluted for the quarter ending 31 Jul 2025 was 6.8M shares, a 13.6% decline year-over-year.
  • PharmaCyte Biotech, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2024 was 7.33M shares, a 23.5% decline from 2023.
  • PharmaCyte Biotech, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2023 was 9.58M shares, a 50.8% decline from 2022.
  • PharmaCyte Biotech, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2022 was 19.5M shares, a 25.6% increase from 2021.
Weighted Average Number of Shares Outstanding, Diluted, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Quarterly Change (%)
Weighted Average Number of Shares Outstanding, Diluted, Annual (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Annual Change (%)

PharmaCyte Biotech, Inc. Quarterly Weighted Average Number of Shares Outstanding, Diluted (shares)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2025 6.8M -1.07M -13.6% 01 May 2025 31 Jul 2025 10-Q 15 Sep 2025
Q1 2025 7.33M -2.25M -23.5% 01 Feb 2025 30 Apr 2025 10-K 11 Aug 2025
Q4 2024 6.96M -1.65M -19.1% 01 Nov 2024 31 Jan 2025 10-Q 17 Mar 2025
Q3 2024 7.64M -1.13M -12.9% 01 Aug 2024 31 Oct 2024 10-Q 13 Dec 2024
Q2 2024 7.87M -4.74M -37.6% 01 May 2024 31 Jul 2024 10-Q 15 Sep 2025
Q1 2024 9.58M -9.91M -50.8% 01 Feb 2024 30 Apr 2024 10-K 11 Aug 2025
Q4 2023 8.61M -10.4M -54.7% 01 Nov 2023 31 Jan 2024 10-Q 17 Mar 2025
Q3 2023 8.77M -11.8M -57.4% 01 Aug 2023 31 Oct 2023 10-Q 13 Dec 2024
Q2 2023 12.6M -8.23M -39.5% 01 May 2023 31 Jul 2023 10-Q 17 Sep 2024
Q1 2023 19.5M +3.97M +25.6% 01 Feb 2023 30 Apr 2023 10-K 13 Aug 2024
Q4 2022 19M -2.67M -12.3% 01 Nov 2022 31 Jan 2023 10-Q 18 Mar 2024
Q3 2022 20.6M +3.23M +18.6% 01 Aug 2022 31 Oct 2022 10-Q 15 Dec 2023
Q2 2022 20.8M +19.2M +1209% 01 May 2022 31 Jul 2022 10-Q 18 Sep 2023
Q1 2022 15.5M +14.1M +972% 01 Feb 2022 30 Apr 2022 10-K 31 Jul 2023
Q4 2021 21.7M +20.1M +1291% 01 Nov 2021 31 Jan 2022 10-Q 16 Mar 2023
Q3 2021 17.4M +15.8M +1028% 01 Aug 2021 31 Oct 2021 10-Q 14 Dec 2022
Q2 2021 1.59M +472K +42.2% 01 May 2021 31 Jul 2021 10-Q 14 Sep 2022
Q1 2021 1.45M +544K +60.2% 01 Feb 2021 30 Apr 2021 10-K 28 Jul 2022
Q4 2020 1.56M -1.37B -99.9% 01 Nov 2020 31 Jan 2021 10-Q 15 Mar 2022
Q3 2020 1.54M -1.32B -99.9% 01 Aug 2020 31 Oct 2020 10-Q 14 Dec 2021
Q2 2020 1.12M -1.21B -99.9% 01 May 2020 31 Jul 2020 10-Q 14 Sep 2021
Q1 2020 904K -1.1B -99.9% 01 Feb 2020 30 Apr 2020 10-K 10 Aug 2021
Q4 2019 1.38B +249M +22.1% 01 Nov 2019 31 Jan 2020 10-Q 12 Mar 2021
Q3 2019 1.33B +244M +22.6% 01 Aug 2019 31 Oct 2019 10-Q 11 Dec 2020
Q2 2019 1.21B +164M +15.7% 01 May 2019 31 Jul 2019 10-Q 11 Sep 2020
Q1 2019 1.1B +131M +13.6% 01 Feb 2019 30 Apr 2019 10-K 13 Aug 2020
Q4 2018 1.13B +151M +15.5% 01 Nov 2018 31 Jan 2019 10-Q 13 Mar 2020
Q3 2018 1.08B +108M +11.1% 01 Aug 2018 31 Oct 2018 10-Q 23 Dec 2019
Q2 2018 1.05B +121M +13.1% 01 May 2018 31 Jul 2018 10-Q 13 Sep 2019
Q1 2018 969M +123M +14.6% 01 Feb 2018 30 Apr 2018 10-K 13 Aug 2019
Q4 2017 976M +116M +13.5% 01 Nov 2017 31 Jan 2018 10-Q 14 Mar 2019
Q3 2017 973M +124M +14.6% 01 Aug 2017 31 Oct 2017 10-Q 14 Dec 2018
Q2 2017 926M +137M +17.4% 01 May 2017 31 Jul 2017 10-Q 12 Sep 2018
Q1 2017 845M +92.9M +12.3% 01 Feb 2017 30 Apr 2017 10-K 20 Jul 2018
Q4 2016 860M +103M +13.6% 01 Nov 2016 31 Jan 2017 10-Q 19 Mar 2018
Q3 2016 849M +104M +13.9% 01 Aug 2016 31 Oct 2016 10-Q 14 Dec 2017
Q2 2016 788M +50.3M +6.81% 01 May 2016 31 Jul 2016 10-Q 13 Sep 2017
Q1 2016 752M 01 Feb 2016 30 Apr 2016 10-K 27 Jul 2017
Q4 2015 757M 01 Nov 2015 31 Jan 2016 10-Q 13 Mar 2017
Q3 2015 745M 01 Aug 2015 31 Oct 2015 10-Q 02 Dec 2016
Q2 2015 738M 01 May 2015 31 Jul 2015 10-Q 06 Sep 2016

PharmaCyte Biotech, Inc. Annual Weighted Average Number of Shares Outstanding, Diluted (shares)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 7.33M -2.25M -23.5% 01 May 2024 30 Apr 2025 10-K 11 Aug 2025
2023 9.58M -9.91M -50.8% 01 May 2023 30 Apr 2024 10-K 11 Aug 2025
2022 19.5M +3.97M +25.6% 01 May 2022 30 Apr 2023 10-K 13 Aug 2024
2021 15.5M +14.1M +972% 01 May 2021 30 Apr 2022 10-K 31 Jul 2023
2020 1.45M +544K +60.2% 01 May 2020 30 Apr 2021 10-K 28 Jul 2022
2019 904K -1.1B -99.9% 01 May 2019 30 Apr 2020 10-K 10 Aug 2021
2018 1.1B +131M +13.6% 01 May 2018 30 Apr 2019 10-K 13 Aug 2020
2017 969M +123M +14.6% 01 May 2017 30 Apr 2018 10-K 13 Aug 2019
2016 845M +92.9M +12.3% 01 May 2016 30 Apr 2017 10-K 20 Jul 2018
2015 752M +48.1M +6.83% 01 May 2015 30 Apr 2016 10-K 27 Jul 2017
2014 704M +121M +20.8% 01 May 2014 30 Apr 2015 10-K 29 Jul 2016
2013 583M +142M +32.3% 01 May 2013 30 Apr 2014 10-K 29 Jul 2016
2012 441M 01 May 2012 30 Apr 2013 10-K/A 19 Jan 2016
* An asterisk sign (*) next to the value indicates that the value is likely invalid.